Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review

Table 3 Efficacy, safety and tolerability of loco-regional treatments for recurrent hepatocellular

Ref.	No. of patients	Treatment	No. of treatments per patient	Efficacy	Side effects	Tolerability	Safety
				(No.of patients)	(No. of patients)
Rivera et al[31]	1	SIRT (Y-90)	1	Efficacy demonstrated by tumor necrosis on imaging and decreased AFP level	Intermittent nausea Mild right upper quadrant abdominal pain	Well tolerated	No adverse consequence
Ho et al[27]	1	RFA	1	No evidence of local progression and normalization of AFP levels	None	Well tolerated	No adverse consequence
Ko et al[49]	28	TACE	2.5	Complete response (3), partial response (11), minimal response (5), stable disease (3), progressive disease (6)	In 17.9% of patients: Nausea, vomiting, diarrhea Hypertension, tachycardia Mild right upper quadrant abdominal pain	Well tolerated	No adverse consequence
Tan et al[80]	10	TACE	NR	According to RECIST criteria, partial response (1), stable disease (3), and progressive disease (6)	NR	Well tolerated	No adverse consequence
Carr[39]	6	TACE	8.2	Complete response (1), partial response (2), stable disease (1), progression (2)	Bilirubin toxicity (Grade 2) (1) Granulocyte toxicity (Grade 3) (3)	Well tolerated	No adverse consequence
Chen et al[77]	4	TACE	2.8	According to mRECIST criteria, complete or partial response in all patients	None	Well tolerated	No adverse consequence
Cheng et al[41]	11	TACE	NR	NR	NR	Well tolerated	No adverse consequence
Zhang et al[67]	10	CT 125I guided brachytherapy	3.9	Complete local control of HCC recurrence 72% of patients at 2 yr	Minor displacement of radioactive seeds (2)	Well tolerated	Hemothorax (1)
					Mild increase of white blood cell counts (3)		Hemosputum (3)
					Fever (4)

CT: Computed tomography; TACE: Transarterial chemoembolization; RFA: Radiofrequency ablation; SIRT: Selective internal radiotherapy treatment; HCC: Hepatocellular carcinoma; LT: Liver transplantation.